EMEA-001501-PIP02-13-M08 - paediatric investigation plan
dupilumab
PIPHuman
Key facts
- Invented name
- Dupixent
- Active Substance
- dupilumab
- Therapeutic area
- Dermatology
- Decision number
- P/0396/2023
- PIP number
- EMEA-001501-PIP02-13-M08
- Pharmaceutical form(s)
- Solution for injection
- Condition(s) / indication(s)
- Treatment of asthma
- Route(s) of administration
- Subcutaneous use
- Contact for public enquiries
Sanofi Winthrop Industrie
E-mail: contact-us@sanofi.com
Tel: +33 1 69 74 56 95- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date